International Journal of Scientific Trends- (IJST)
ISSN: 2980-4299
Volume 4, Issue 4, April - 2025
Website: https://scientifictrends.org/index.php/ijst
Open Access, Peer Reviewed, Scientific Journal

Surfactant Therapy in Premature Infants: A Critical Tool in Neonatal Care

Rustamov Bakhtiyorjon
Bukhara State Medical Institute,
Assistant of the 2 Pediatrics Department

Abstract

Premature birth is a major contributor to neonatal morbidity and mortality, with respiratory distress syndrome (RDS) representing one of the most critical complications. Surfactant therapy has revolutionized the management of RDS in preterm infants, significantly improving survival and reducing pulmonary complications. This article reviews the physiology of surfactant, the pathophysiology of RDS, the types of surfactant preparations available, administration techniques, timing of therapy, and current best practices.

Keywords: Respiratory distress syndrome (RDS), very low birth weight (VLBW), Incidence of Bronchopulmonary Dysplasia (BPD), Oxygen Saturation and Blood Gas Levels, Surfactant proteins (SP-A and SP-D), neonatal intensive care unit (NICU), randomized controlled trial (RCT).

Introduction

Preterm birth, defined as delivery before 37 weeks of gestation, accounts for approximately 10% of live births worldwide. Among the many challenges faced by premature infants, respiratory distress syndrome (RDS) is the most common and serious. RDS results from a deficiency of pulmonary surfactant, a substance critical for reducing alveolar surface tension and maintaining lung compliance. The introduction of exogenous surfactant therapy in the 1980s has since become a cornerstone of neonatal intensive care, dramatically altering the prognosis of affected infants [1,5].

Surfactant Physiology Pulmonary surfactant is a complex mixture of lipids and proteins secreted by type II alveolar cells. It functions to reduce the surface tension at the air-liquid interface within the alveoli, preventing alveolar collapse during expiration and thus ensuring efficient gas exchange. Surfactant production begins around the 24th to 28th week of gestation and becomes adequate by 34 to 36 weeks, rendering extremely preterm infants particularly susceptible to surfactant deficiency [2].

Pathophysiology of RDS In premature infants, immature lungs produce insufficient surfactant, resulting in high surface tension, atelectasis, impaired gas exchange, and hypoxemia. Histologically, RDS is characterized by collapsed alveoli and the formation of hyaline membranes,

leading to decreased lung compliance and increased work of breathing. Without intervention, RDS can rapidly progress to respiratory failure and death[3,4].

Surfactant Therapy: History and Development The first successful clinical use of exogenous surfactant was reported in 1980. Since then, multiple surfactant preparations have been developed, including both natural (animal-derived) and synthetic formulations. Natural surfactants (e.g., beractant, poractant alfa) contain surfactant proteins that enhance efficacy, while newer synthetic formulations aim to mimic these properties without animal components[6].

Indications and Timing Surfactant therapy is primarily indicated for the treatment and prevention of RDS in premature infants. Prophylactic administration within minutes after birth may benefit infants at high risk (<28 weeks gestation), whereas early rescue therapy is recommended for infants who develop clinical signs of RDS. Studies have shown that early administration (within the first 2 hours of life) leads to better outcomes than delayed treatment[7,9].

Administration Techniques Traditionally, surfactant is delivered via endotracheal intubation and mechanical ventilation. However, concerns about ventilator-associated lung injury have led to the development of less invasive methods, including the INSURE technique (Intubate, SURfactant, Extubate) and LISA (Less Invasive Surfactant Administration), where surfactant is administered through a thin catheter while the infant breathes spontaneously on CPAP[8,10].

Clinical Assessment. 1. Parameters of respiration Monitoring includes measuring arterial blood gases, respiratory rate, and oxygen saturation both before and after surfactant delivery. Assessment of the infant's post-treatment positive airway pressure requirements and need for mechanical ventilation.

2. Clinical Ratings: To evaluate clinical progress in respiratory status, grading methods like the Neonatal RDS Severity Score and the Silverman Score are used. Keep an eye out for indications of better lung function, less respiratory effort, and general clinical stability.

3. Immediate and Prolonged Results: Monitoring the incidence of bronchopulmonary dysplasia (BPD), days spent on mechanical ventilation, and duration of stay in the newborn intensive care unit (NICU).

Evaluations of the child's neurological and respiratory development over an extended period of time.

Immunological Assessment. 1. Biomarker Studies: To evaluate lung inflammation after surfactant treatment, inflammatory markers (such as interleukins and cytokines) are measured in blood or tracheal aspirates. Monitoring levels of surfactant proteins (SP-A, SP-B) to assess lung function and the efficacy of surfactant replacement.

2. Pulmonary Function Tests: - Performing tests like plethysmography or oscillometry to evaluate lung mechanics after therapy, especially when the infants live to a later age. Assessing respiratory resistance and compliance, which may be a sign of how well surfactant treatment is working.

3. Immunological Response Assessment: T-cell populations, natural killer (NK) cells, and other immunological markers in the blood are measured in order to analyse the immune response.

Evaluation of general immune function, including the existence of infections or sepsis, which may impede the effectiveness of surfactant therapy.

Imaging Methods. 1. Chest X-rays and ultrasounds: routine imaging tests to evaluate the structure and function of the lungs, searching for atelectasis symptoms and improvements in lung expansion following the administration of surfactants.

Lung aeration can also be measured in real time using ultrasound.

2. High-Resolution Computed Tomography (HRCT): In some situations, HRCT scans can be used to study long-term results and chronic lung illness, as well as to provide a complete evaluation of lung architecture and any damage following surfactant therapy. Investigations and Developments ongoing research on the unique impact of novel surfactant formulations (such as synthetic and protein-rich surfactants) on the immune response research on supplemental treatments (such postnatal corticosteroids) that might improve surfactant therapy's efficacy and have an impact on long-term results. Assessment of Surfactant Therapy's Clinical and Immunological Effectiveness in Premature Infants with Very Low Body Weight (VLBW) This describes a possible research design that takes into account both clinical and immunological factors in order to assess the efficacy of surfactant treatment in VLBW preterm newborns.

I. Overview: Surfactant insufficiency puts premature newborns at increased risk for respiratory distress syndrome (RDS), particularly those with very low birth weights (VLBW, <1500g). A vital component of newborn care, surfactant replacement treatment dramatically increases survival and lowers morbidity. Research is still ongoing to determine the best practices and the long-term immunological implications, though. The purpose of this study is to thoroughly evaluate the immunological and clinical effects of surfactant treatment in VLBW newborns.

II. Research Design: The most reliable design would be an RCT, or randomised controlled experiment. Participants: VLBW babies (less than 1500 grammes) who were diagnosed with or at high risk for RDS and admitted to the Neonatal Intensive Care Unit (NICU). Clear definitions of the inclusion and exclusion criteria (such as congenital defects, serious infections, and substantial co-morbidities) will be provided.

Using randomisation Participants will be split into one of two groups at random: Intervention group: Getting surfactant treatment (name the kind and dose schedule). Standard care, maybe with supported breathing but without surfactant, is given to the control group. It might not be morally acceptable to conduct a placebo-controlled experiment. An alternative dose schedule or comparison to another surfactant could also be taken into account.

Blinding: Although it might be difficult in this situation to blind physicians and assessors, efforts should be taken to reduce bias by using standardised data collecting methods and, when practical, blinded evaluations (such as radiological interpretation).

The sample size was determined using power analysis and clinically relevant objectives, such as the incidence of bronchopulmonary dysplasia (BPD), length of mechanical ventilation, and mortality reduction.

III. Results in Clinical Practice: Principal Results: mortality rate at 28 days and 36 weeks of corrected gestation. length of time spent on mechanical ventilation. BPD prevalence and severity at corrected gestational age of 36 weeks. Extracorporeal membrane oxygenation (ECMO) is required.

Secondary Results: duration of hospitalization indicators of oxygen saturation.

requires for respiratory assistance, such as nasal continuous positive airway pressure (CPAP) and high-frequency oscillatory ventilation prevalence of other respiratory issues, such as pulmonary haemorrhage and pneumothorax.

Growth metrics (head circumference, weight, and length) neurodevelopmental outcomes (e.g., Bayley Scales of Infant Development) at 18–24 months.

Outcomes and Complications Surfactant therapy has significantly reduced the incidence of mortality and air leak syndromes such as pneumothorax in premature infants. Nevertheless, potential complications include transient bradycardia, oxygen desaturation, and pulmonary hemorrhage. Long-term pulmonary outcomes, including the risk of bronchopulmonary dysplasia (BPD), are influenced by the severity of RDS and the mode of respiratory support used in conjunction with surfactant therapy.

Current Guidelines and Recommendations Organizations such as the American Academy of Pediatrics (AAP) and European Consensus Guidelines recommend early use of CPAP in spontaneously breathing infants, with selective surfactant administration for those showing signs of RDS. The choice of surfactant preparation, timing, and delivery method should be individualized based on gestational age, clinical status, and institutional protocols.

Future Directions Ongoing research aims to refine surfactant formulations, improve delivery methods, and integrate surfactant therapy into broader strategies for lung protection. Promising areas include aerosolized surfactant, combination therapy with anti-inflammatory agents, and genetic approaches to enhance endogenous surfactant production.

Conclusion. Surfactant therapy remains a life-saving intervention in the care of premature infants with RDS. Continued advances in administration techniques and supportive care will further improve outcomes. Early recognition, appropriate timing, and a less invasive approach are key to maximizing the benefits of this essential neonatal therapy.

REFERENCES

1. Polin RA, Carlo WA. Surfactant Replacement Therapy for Preterm and Term Neonates With Respiratory Distress. Pediatrics. 2014.
2. Sweet DG, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2022 Update. Neonatology.
3. Jobe AH, Ikegami M. Mechanisms Initiating Lung Injury in the Preterm. Early Hum Dev. 1998.
4. Mead, J., and Avery, M. E. (1959). Surface characteristics in connection with hyaline membrane illness and atelectasis. AMA Children's Diseases Journal, 97(5), 517-523.
5. Ikegami, M., and Jobe, A. H. (1998). mechanisms that cause lung damage in premature infants. 53(1), 81-94; Early Human Development.
6. Richmond, P., Simmer, K., Strunk, T., Currie, A., & Burgner, D. (2011). Human newborns with innate immunity: preterm is more than just immaturity. 24(1), 25–31; Journal of Maternal-Fetal & Neonatal Medicine.
7. Moss, T. J. M., and Melville, J. M. (2013). the effects of premature birth on the immune system. Neuroscience Frontiers, 7, 79.
8. Ballard, R. A., and P. L. Ballard (1995). Prenatal glucocorticoid use: scientific foundation and treatment plans. 173(1), 254-262, American Journal of Obstetrics and Gynaecology.
9. Morley, C. J., and R. F. Soll (2001). Using surfactant prophylactically as opposed to selectively can help reduce morbidity and death in premature babies. Database of Systematic Reviews, Cochrane, 2.

10. Bose, C., Van Marter, L. J., Allred, E. N., O'Shea, T. M., & Laughon, M. (2011). Developmental delay and chronic lung illness at age two in children born before 28 weeks. e726–e732 in Paediatrics, 127(3).

11. Fanaroff, A. A., and Hack, M. (2000). results of infants born in the 1990s with exceptionally low gestational ages and birthweights. 1953(3), Early Human Development, 193-218.